Comparison of Prostate Specific Antigen Velocity in Screened Versus Referred Patients With Prostate Cancer

Journal of Urology

Volumn 179, Issue 4, 2008, Pages 1340-1343

  Meeks, Joshua J ^a   Thaxton, C Shad ^a   Loeb, Stacy ^b   Roehl, Kimberly A ^c   Helfand, Brian T ^a   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

mass screening; mortality; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION;

EID: 40849140583     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.11.068     Document Type: Article

References (21)

1. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U. S. (1969-2004). National Cancer Institute, Division of Cancer control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2007. www.seer.cancer.gov Accessed July 28, 2007
2. Monitoring the Nation's Health. National Center for Health Statistics, vol 2007. www.cdc.gov/nchs Accessed July 28, 2007
3. Bartsch G., Horninger W., Klocker H., Reissigl A., Oberaigner W., Schonitzer D., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417
4. Roehl K.A., Eggener S.E., Loeb S., Smith N.D., Antenor J.A., and Catalona W.J. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol 24 (2006) 465
5. Talcott J.A. What patients should be told before agreeing to a blood test that could change their lives. Urology 61 (2003) 7
6. Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A., Schroder F.H., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868
7. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
8. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
9. Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521
10. Smith D.S., Humphrey P.A., and Catalona W.J. The early detection of prostate carcinoma with prostate specific antigen. Cancer 80 (1997) 1852
11. Yu X., Loeb S., Roehl K.A., Han M., and Catalona W.J. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol 177 (2007) 1298
12. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., and Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 (2002) 740
13. Jemal A., Ward E., Wu X., Martin H.J., McLaughlin C.C., and Thun M.J. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14 (2005) 590
14. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., Wildhagen M.F., de Koning H.J., van der Kwast T.H., et al. Comparison of sreeen detected and clinically diagnosed prostate cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. J Urol 174 (2005) 121
15. Postma R., Schroder F.H., van Leenders G.J.L.H., Hoedemaeker R.F., Vis A.N., Roobol M.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89
16. van der Cruijsen-Koeter I.W., Roobol M.J., Wildhagen M.F., van der Kwast T.H., Kirkels W.J., and Schroder F.H. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 68 (2006) 615
17. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981
18. Graif T., Loeb S., Roehl K.A., Gashti S.N., Griffin C., Yu X., et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 178 (2007) 88
19. Pinsky P., Andriole G.E., Crawford D., Chia D., Kramer B.S., Grubb R., et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 109 (2007) 1689
20. Vis A.N., Roemeling S., Reedijk A.M., Otto S.J., and Schroder F.H. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort. Eur Urol 53 (2008) 91
21. Lujan M., Paez A., Pascual C., Angulo J., Miravalles E., and Berenguer A. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 50 (2006) 1234